Next Article in Journal
Therapeutic Potential of Brazilian Cerrado Campomanesia Species on Metabolic Dysfunctions
Previous Article in Journal
Suppressive Effects of EGCG on Cervical Cancer
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessCommunication
Molecules 2018, 23(9), 2335; https://doi.org/10.3390/molecules23092335

Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

1
Department for Molecular and Cellular Mechanisms of Neurodegeneration, Paul Flechsig Institute for Brain Research, University of Leipzig, Liebigstraße 19, 04103 Leipzig, Germany
2
Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany
3
Department of Neurology, University of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany
4
ProQinase GmbH Freiburg, Breisacher Straße 117, 79106 Freiburg, Germany
*
Author to whom correspondence should be addressed.
Received: 27 June 2018 / Revised: 6 September 2018 / Accepted: 8 September 2018 / Published: 12 September 2018
(This article belongs to the Section Medicinal Chemistry)
Full-Text   |   PDF [1205 KB, uploaded 12 September 2018]   |  

Abstract

The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There have been many approaches for a reduction of toxic Aβ peptides which mostly failed to halt cognitive deterioration in patients. The formation of neurofibrillary tangles (NFT) and its precursor tau oligomers have been suggested as main cause of neuronal degeneration because of a direct correlation of their density to the degree of dementia. Reducing of tau aggregation may be a viable approach for the treatment of AD. NFT consist of hyperphosphorylated tau protein and tau hyperphosphorylation reduces microtubule binding. Several protein kinases are discussed to be involved in tau hyperphosphorylation. We developed novel inhibitors of three protein kinases (gsk-3β, cdk5, and cdk1) and discussed their activity in relation to tau phosphorylation and on tau–tau interaction as a nucleation stage of a tau aggregation in cells. Strongest effects were observed for those inhibitors with effects on all the three kinases with emphasis on gsk-3β in nanomolar ranges. View Full-Text
Keywords: AD drug discovery; synthesis; derivatives; structure-activity; lead structure AD drug discovery; synthesis; derivatives; structure-activity; lead structure
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Holzer, M.; Schade, N.; Opitz, A.; Hilbrich, I.; Stieler, J.; Vogel, T.; Neukel, V.; Oberstadt, M.; Totzke, F.; Schächtele, C.; Sippl, W.; Hilgeroth, A. Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay. Molecules 2018, 23, 2335.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top